Combivir is a drug owned by Viiv Healthcare Co. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 18, 2016. Details of Combivir's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5905082 (Pediatric) | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) |
Expired
|
| US5905082 | Crystalline oxathiolane derivatives |
May, 2016
(8 years ago) |
Expired
|
|
US5859021 (Pediatric) | Antiviral combinations |
Nov, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Combivir is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Combivir's family patents as well as insights into ongoing legal events on those patents.
Combivir's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Combivir's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 18, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Combivir Generic API suppliers:
Lamivudine; Zidovudine is the generic name for the brand Combivir. 12 different companies have already filed for the generic of Combivir, with Aurobindo Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Combivir's generic
Alternative Brands for Combivir
Combivir which is used for the treatment of HIV., has several other brand drugs in the same treatment category and using the same active ingredient (Lamivudine; Zidovudine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Agouron Pharms |
| |||||
| Bristol Myers Squibb |
| |||||
| Gilead |
| |||||
| Gilead Sciences Inc |
| |||||
| Roche |
| |||||
| Viiv Hlthcare |
| |||||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Lamivudine; Zidovudine, Combivir's active ingredient. Check the complete list of approved generic manufacturers for Combivir
About Combivir
Combivir is a drug owned by Viiv Healthcare Co. It is used for the treatment of HIV. Combivir uses Lamivudine; Zidovudine as an active ingredient. Combivir was launched by Viiv Hlthcare in 1997.
Approval Date:
Combivir was approved by FDA for market use on 26 September, 1997.
Active Ingredient:
Combivir uses Lamivudine; Zidovudine as the active ingredient. Check out other Drugs and Companies using Lamivudine; Zidovudine ingredient
Treatment:
Combivir is used for the treatment of HIV.
Dosage:
Combivir is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150MG;300MG | TABLET | Discontinued | ORAL |